ImmunOs Therapeutics

Executive Summary

ImmunOs Therapeutics is a Swiss private biopharmaceutical company founded in 2016, headquartered in Schlieren, Switzerland. The company focuses on developing novel immune-modulating therapies across multiple modalities including antibodies, biologics, and small molecules. Although specific pipeline details are not publicly disclosed, ImmunOs aims to address unmet needs in immuno-oncology and autoimmune diseases by leveraging platforms that target key immune checkpoints and regulatory pathways. The company's strategy likely involves advancing proprietary candidates toward clinical development, with potential for partnerships or licensing deals. Given its early-stage nature, ImmunOs represents a high-risk, high-reward opportunity in the competitive immunotherapy landscape.

Upcoming Catalysts (preview)

• Q1 2027Initiation of Phase 1 clinical trial for lead candidate IOS-10130% success
• Q2 2026Presentation of preclinical data for a novel bispecific antibody at a major oncology conference60% success
• Q4 2026Announcement of strategic partnership or licensing deal for one of its platforms40% success